中性粒细胞在胶质瘤中的作用及应用研究进展

doi:10.3969/j.issn.1006-7795.2025.03.008

摘要/Abstract

摘要： 中性粒细胞是人体最丰富的白细胞，在不同的疾病中发挥着不同的作用。中性粒细胞作为肿瘤免疫微环境（tumor microenvironment，TME）中的重要组成成分，在肿瘤发生发展中扮演着关键的角色，存在促肿瘤和抗肿瘤的双重作用。本文深入讨论了中性粒细胞的募集、分型以及其对肿瘤的双重作用，同时探索了中性粒细胞在胶质瘤中的作用和临床意义。肿瘤靶向中性粒细胞的治疗方法为后续肿瘤的治疗提供了新的治疗方向，尤其像中枢神经系统肿瘤，中性粒细胞载体可携带药物穿过血－脑脊液屏障到达肿瘤组织，为后续脑肿瘤的治疗提供了新的希望。

关键词: 炎症, 中性粒细胞, 中性粒细胞外陷阱, 肿瘤, 胶质瘤

Abstract: Neutrophils are the most abundant white blood cells in the human body and play different roles in various diseases. The studies have shown that inflammation is closely related to the occurrence and development of tumors. As an important component of the tumor microenvironment (TME), neutrophils play a crucial role in tumors and have a dual effect of promoting and inhibiting tumor growth. This article deeply discusses the recruitment and subtypes of neutrophils, as well their dual effects on tumors. Meanwhile, it illustrates the role and clinical significance of neutrophils in gliomas. The therapeutic approach of targeting neutrophils in tumors provides a new direction for subsequent tumor treatment. Especially for central nervous system tumors, neutrophils as carriers can transport chemotherapeutic drugs across the blood-brain barrier to reach the tumor tissue, offering new hope for the subsequent treatment of brain tumors.

Key words: inflammation, neutrophils, neutrophil extracellular traps, , tumors, gliomas

中图分类号:

R739.4

蒋海萍, 尹硕, 李生兰, 李文斌. 中性粒细胞在胶质瘤中的作用及应用研究进展[J]. 首都医科大学学报, 2025, 46(3): 448-454.

Jiang Haiping, Yin Shuo, Li Shenglan, Li Wenbin. The progress in the role and application of neutrophils in glioma[J]. Journal of Capital Medical University, 2025, 46(3): 448-454.

参考文献

［1］Zhao H K, Wu L, Yan G F, et al. Inflammation and tumor progression: signaling pathways and targeted intervention［J］. Signal Transduct Target Ther, 2021, 6(1): 263.
［2］Schaff L R, Mellinghoff I K. Glioblastoma and other primary brain malignancies in adults: a review［J］. JAMA, 2023, 329(7): 574－587.
［3］Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial［J］. JAMA, 2017, 318(23): 2306－2316.
［4］Xiao C Y, Feng X, Aini W, et al. Knowledge landscape of tumor-associated neutrophil: a bibliometric and visual analysis from 2000-2024［J］. Front Immunol, 2024, 15: 1448818.
［5］Calzetti F, Finotti G, Cassatella M A. Current knowledge on the early stages of human neutropoiesis［J］. Immunol Rev, 2023, 314(1): 111－124.
［6］SenGupta S, Hein L E, Parent C A. The recruitment of neutrophils to the tumor microenvironment is regulated by multiple mediators［J］. Front Immunol, 2021, 12: 734188.
［7］Korbecki J, Kupnicka P, Chlubek M, et al. CXCR2 receptor: regulation of expression, signal transduction, and involvement in cancer［J］. Int J Mol Sci, 2022, 23(4): 2168.
［8］Ji H Z, Liu B, Ren M, et al. The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer［J］. Expert Rev Clin Immunol, 2024, 20(5): 559－569.
［9］Lin Y, Cheng L, Liu Y, et al. Intestinal epithelium-derived BATF3 promotes colitis-associated colon cancer through facilitating CXCL5-mediated neutrophils recruitment［J］. Mucosal Immunol, 2021, 14(1): 187－198.
［10］Fridlender Z G, Sun J, Kim S, et al.Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN［J］. Cancer Cell, 2009, 16(3): 183－194.
［11］Andzinski L, Kasnitz N, Stahnke S, et al. Type IIFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human［J］. Int J Cancer, 2016, 138(8): 1982-1993.
［12］Jing W, Wang G, Cui Z, et al. Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression［J］. Proc Natl Acad Sci U S A, 2024, 121(20): e2312855121.
［13］De Meo M L, Spicer J D. The role of neutrophil extracellular traps in cancer progression and metastasis［J］. Semin Immunol, 2021, 57: 101595.
［14］Xiao Y S, Cong M, Li J T, et al. Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation［J］. Cancer Cell, 2021, 39(3): 423－437.e7.
［15］Rayes R F, Mouhanna J G, Nicolau I, et al. Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects［J］. JCI Insight, 2019, 5(16): 128008.
［16］Zhang Y, Guo L P, Dai Q C, et al. A signature for pan-cancer prognosis based on neutrophil extracellular traps［J］. J Immunother Cancer, 2022, 10(6): e004210.
［17］Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy［J］. Cancer Sci, 2008, 99(8): 1501-1506.
［18］Bordbari S, Mörchen B, Pylaeva E, et al. SIRT1-mediated deacetylation of FOXO3a transcription factor supports pro-angiogenic activity of interferon-deficient tumor-associated neutrophils［J］. Int J Cancer, 2022, 150(7): 1198－1211.
［19］Behrens L M, van Egmond M, van den Berg T K. Neutrophils as immune effector cells in antibody therapy in cancer［J］. Immunol Rev, 2023, 314(1): 280－301.
［20］Gungabeesoon J, Gort-Freitas NA, Kiss M, et al. A neutrophil response linked to tumor control in immunotherapy［J］. Cell, 2023, 186(7): 1448－1464.e20.
［21］Xu P, Zhang X, Chen K, et al. Tumor cell-derived microparticles induced by methotrexate augment T-cell antitumor responses by downregulating expression of PD-1 in neutrophils［J］. Cancer Immunol Res, 2023, 11(4): 501－514.
［22］Quaas A, Pamuk A, Klein S, et al. Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma［J］. Gastric Cancer, 2021, 24(6): 1213－1226.
［23］Triner D, Devenport S N, Ramakrishnan S K, et al. Neutrophils restrict tumor-associated microbiota to reduce growth and invasion of colon tumors in mice［J］. Gastroenterology, 2019, 156(5): 1467－1482.
［24］Chen C L, Wang Y, Huang C Y, et al. IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma［J］. Oncoimmunology, 2017, 7(1): e1373234.
［25］Hsu E J, Thomas J, Maher E A, et al. Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients［J］. Front Oncol, 2022, 12: 1000280.
［26］Maas R R, Soukup K, Fournier N, et al. The local microenvironment drives activation of neutrophils in human brain tumors［J］. Cell, 2023, 186(21): 4546－4566.
［27］Huang N, Tang J, Yi X, et al. Glioma-derived S100A9 polarizes M2 microglia to inhibit CD8+T lymphocytes for immunosuppression viaαvβ3 integrin/AKT1/TGFβ1［J］. Biochim Biophys Acta Mol Cell Res, 2024, 1871(1): 119619.
［28］Liang J, Piao Y J, Holmes L, et al. Neutrophils promote the malignant glioma phenotype through S100A4［J］. Clin Cancer Res, 2014, 20(1): 187－198.
［29］Inukai M, Yokoi A, Ishizuka Y, et al. A functional role of S100A4/non-muscle myosin IIA axis for pro-tumorigenic vascular functions in glioblastoma［J］. Cell Commun Signal, 2022, 20(1): 46.
［30］Jiguet-Jiglaire C, Boissonneau S, Denicolai E, et al. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study［J］. Acta Neuropathol Commun, 2022, 10(1): 1.
［31］Zha C J, Meng X Q, Li L L, et al. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis［J］. Cancer Biol Med, 2020, 17(1): 154－168.
［32］Wang X Z, Li A A, Wu Y F, et al. The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification)［J］. BMC Cancer, 2023, 23(1): 20.
［33］Sun C, Wang S W, Ma Z, et al. Neutrophils in glioma microenvironment: from immune function to immunotherapy［J］. Front Immunol, 2024, 15: 1393173.
［34］Lad M, Beniwal A S, Jain S, et al. Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow［J］. Cancer Cell, 2024, 42(9): 1549－1569.e16.
［35］Tsai H C, Tong Z J, Hwang T L, et al. Acrolein produced by glioma cells under hypoxia inhibits neutrophil AKT activity and suppresses anti-tumoral activities［J］. Free Radic Biol Med, 2023, 207: 17－28.
［36］Lei Y Y, Li Y T, Hu Q L, et al. Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis［J］. World J Surg Oncol, 2019, 17(1): 152.
［37］Zhang M, Huang L, Ding G, et al. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer［J］. J Immunother Cancer, 2020, 8(1): e000308.
［38］Cheng Y, Mo F, Li Q F, et al. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin［J］. Mol Cancer, 2021, 20(1): 62.
［39］Flores-Toro J A, Luo D, Gopinath A, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas［J］. Proc Natl Acad Sci U S A, 2020, 117(2): 1129－1138.
［40］Deng H, Lin C, Garcia-Gerique L, et al. A novel selective inhibitor JBI-589 targets PAD4-mediated neutrophil migration to suppress tumor progression［J］. Cancer Res, 2022, 82(19): 3561－3572.
［41］Wang Z Z, Chen C, Shi C D, et al. Cell membrane derived liposomes loaded with DNase I target neutrophil extracellular traps which inhibits colorectal cancer liver metastases［J］. J Control Release, 2023, 357: 620－629.
［42］Dai W W, Tian R T, Yu L B, et al. Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma［J］. Nat Commun, 2024, 15(1): 131.
［43］Gilbert M R, Dignam J J, Armstrong T S, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma［J］. N Engl J Med, 2014, 370(8): 699－708.
［44］Abdelfattah N, Kumar P, Wang C, et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target［J］. Nat Commun, 2022, 13(1): 767.
［45］Han X J, Gong C N, Yang Q R, et al. Biomimetic nano-drug delivery system: an emerging platform for promoting tumor treatment［J］. Int J Nanomedicine, 2024, 19: 571－608.
［46］Su Y J, Gao J, Dong X Y, et al. Neutrophil-mediated delivery of nanocrystal drugs via photoinduced inflammation enhances cancer therapy［J］. ACS Nano, 2023, 17(16): 15542－15555.
［47］Wang J, Tang W, Yang M, et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy［J］. Biomaterials, 2021, 273: 120784.
［48］Xue J, Zhao Z, Zhang L, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence［J］. Nat Nanotechnol，2017,12(7):692-700.
［49］Li Y J, Teng X C, Wang Y J, et al. Neutrophil delivered hollow Titania covered persistent luminescent nanosensitizer for ultrosound augmented chemo/immuno glioblastoma therapy［J］. Adv Sci (Weinh), 2021, 8(17): e2004381.
［50］Piao C X, Lee J, Kim G E, et al. Targeted delivery of nanoparticle-conveyed neutrophils to the glioblastoma site for efficient therapy［J］. ACS Appl Mater Interfaces, 2024, 16(32): 41819－41827.
［51］Li C, Hendrikse N W, Mai M, et al. Microliter whole blood neutrophil assay preserving physiological lifespan and functional heterogeneity［J］. Small Methods, 2024, 8(9): e2400373.
［52］Wang X H, Zhang H, Chen X H, et al. Overcoming tumor microenvironment obstacles: current approaches for boosting nanodrug delivery［J］. Acta Biomater,2023, 166: 42－68.
［53］Lundy D J, Nguye^~n H, Hsieh P C H. Emerging nano-carrier strategies for brain tumor drug delivery and considerations for clinical translation［J］. Pharmaceutics, 2021, 13(8): 1193.
［54］Al Refaai K A, AlSawaftah N A, Abuwatfa W, et al. Drug release via ultrasound-activated nanocarriers for cancer treatment: A review［J］. Pharmaceutics, 2024, 16(11): 1383.
［55］Shang L H, Jiang X, Yang T, et al. Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment［J］. Acta Pharm Sin B, 2022, 12(5): 2550－2567.

[1]	孙文静, 赵梦冉, 徐俊玄, 张政, 李鹏. 中药单体红景天素靶向幽门螺杆菌脲酶活性中心的抑制机制及胃黏膜保护作用[J]. 首都医科大学学报, 2025, 46(4): 654-662.
[2]	刘思凡, 杨舒悦, 冀旭, 张政, 李鹏. 胃微生物在胃癌进展中的作用[J]. 首都医科大学学报, 2025, 46(4): 682-687.
[3]	刘晓倩, 孙凯, 王晓琳, 赵倩倩, 武笑笑, 沈方琪, 陈曦, 田晨旭, 吴迪, 宋春花, 许红霞, 丛明华, 石汉平, 贾平平. 15种营养/炎症指标对手术后肿瘤患者的预后预测能力比较[J]. 首都医科大学学报, 2025, 46(3): 410-419.
[4]	徐龙薇, 王亚丹, 周敏思, 吴静. 中性粒细胞和巨噬细胞在嗜酸性胃肠炎小鼠各组织中的浸润情况分析[J]. 首都医科大学学报, 2025, 46(2): 306-313.
[5]	安琪, 杨楠, 朱玥荃, 师文娟, 黄敏琪, 赵咏梅. 自噬抑制剂3-MA对脑缺血再灌注损伤大鼠脑内炎症反应的影响[J]. 首都医科大学学报, 2024, 45(6): 1008-1015.
[6]	孙婧, 辛灵恩, 冯贤珍, 丁雨璇, 张玉彪, 王佳. 白芍总苷对脂多糖诱导的小鼠急性肺损伤的保护作用及机制[J]. 首都医科大学学报, 2024, 45(2): 302-311.
[7]	魏星月, 王连双, 王媛媛, 高孟泽, 何琼, 张瑶, 罗建文. 基于多模态超声成像数据的慢性肝病肝纤维化、炎症和脂肪变性的智能分级诊断[J]. 首都医科大学学报, 2023, 44(6): 928-935.
[8]	刘秀, 李文才. UNC0379对胶质瘤细胞增殖影响的初步探索[J]. 首都医科大学学报, 2023, 44(5): 741-746.
[9]	陈彦, 张须龙, 许江南, 贾玉峰, 孙英. 现代免疫学在感染性疾病、过敏性疾病、肿瘤和神经系统疾病中的研究进展[J]. 首都医科大学学报, 2023, 44(2): 179-185.